 RALEIGH, NC ACCESSWIRE June 24, 2020 9 Meters Biopharma, Inc. NMTR, a clinical-stage rare and unmet needs-focused gastroenterology company, today announced it has initiated its Phase 1b2a clinical trial of NM-002 for the treatment of short bowel syndrome SBS, a life-threatening orphan disease caused by a significant shortening of the gastrointestinal tract, leading to impaired nutrient absorption. The Phase 1b2a clinical trial of NM-002 is an open-label, single-center study evaluating the safety and tolerability of three escalating doses of NM-002 in adult patients with SBS. Parental support is a current treatment option used to intravenously provide SBS patients with hydration, essential nutrients and electrolytes. 